Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2016 / N 2

Распространенный (метастатический) рак предстательной железы у лиц старшей возрастной группы: современный взгляд на лечение
Е.В. Дарий

1. Алексеев Б. Я., Нюшко К.М. Комбинированное лечение рака предстательной железы. Онкоурология 2012; 4: 77–82.
2. Howlader N., Krapcho M., Garshell J., Miller D., Altekruse S., Kosary C. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute 2014.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
4. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11–30.
5. Pal S., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010; 60(2): 120–132.
6. Bylow K., Dale W., Mustian K., Stadler W., Rodin M., Hall W., Lachs M., Mohile S. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 2008; 72(2): 422–427.
7. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25(14): 1824–1831.
8. Mohile S., Dale W., Hurria A. Geriatric oncology research to improve clinical care. Nat Rev Clin Oncol 2012; 9(10): 571–578.
9. Rao A., Hsieh F., Feussner J., Cohen H. Geriatric evaluation and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci 2005; 60(6): 798–803.
10. Kotwal A., Mohile S., Dale W. Remaining life expectancy measurement and PSA screening of older men. J Geriatr Oncol 2012; 3(3): 196–204.
11. Extermann M., Aapro M., Bernabei R., Cohen H., Droz J., Lichtman S., Mor V., Monfardini S., Repetto L., Sørbye L., Topinkova E. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society ofGeriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55(3): 241–252.
12. Buskirk S., Pisansky T., Schild S., Macdonald O., Wehle M., Kozelsky T., Collie A., Ferrigni R., Myers R., Prussak K., Heckman M., Crook J., Parker A., Igel T. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006; 176 (3): 985–990.
13. Buyyounouski M., Pickles T., Kestin L., Allison R., Williams S. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012; 30(15): 1857–1863.
14. Walter L., Covinsky K. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285(21): 2750–2756.
15. Loblaw D., Virgo K., Nam R., Somerfield M., Ben-Josef E., Mendelson D., Middleton R., Sharp S., Smith T., Talcott J., Taplin M., Vogelzang N., Wade J., Bennett C., Scher H. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25(12): 1596–1605.
16. D'Amico A., Cote K., Loffredo M., Renshaw A., Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20(23): 4567–4573.
17. Moul J., Wu H., Sun L., McLeod D., Amling C., Donahue T., Kusuda L., Sexton W., O'Reilly K., Hernandez J., Chung A., Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171(3): 1141–1147.
18. Pickles T., Agranovich A., Berthelet E., Duncan G., Keyes M., Kwan W., McKenzie M., Morris W.; British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 2002; 94(2): 362–367.
19. Mohile S., Mustian K., Bylow K., Hall W., Dale W. Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology Hematology 2009; 70(3): 235–255.
20. Bylow K., Mohile S., Stadler W., Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer 2007; 110(12): 2604–2613.
21. Bylow K., Hemmerich J., Mohile S., Stadler W., Sajid S., Dale W. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case–control study. Urology 2011; 77(4): 934–940.
22. Keating N., O'Malley A., Freedland S., Smith M. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102 (1): 39–46.
23. Crook J., O'Callaghan C., Duncan G., Dearnaley D., Higano C., Horwitz E., Frymire E., Malone S., Chin J., Nabid A., Warde P., Corbett T., Angyalfi S., Goldenberg S., Gospodarowicz M., Saad F., Logue J., Hall E., Schellhammer P., Ding K., Klotz L. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367(10): 895–903.
24. Rosenzweig J., Ferrannini E., Grundy S., Haffner S., Heine R., Horton E.; Kawamori R; Endocrine Society. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(10): 3671–3689.
25. Chodak G., Sharifi R., Kasimis B., Block N., MaCramalla E., Kennealey G. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46(6): 849–855.
26. Iversen P. Antiandrogen monotherapy: indications and results. Urology 2002; 60 (3, Suppl 1): 64–71.
27. Tay M., Kaufman DS, Regan M., Leibowitz S., George D., Febbo P., Manola J., Smith M., Kaplan I., Kantoff P., Oh W. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 2004; 15(6): 974–978.
28. Monk J., Halabi S., Picus J., Hussain A., Philips G., Kaplan E., Ahles T., Gu L., Vogelzang N., Kelly W., Small E.; Cancer and Leukemia Group B. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer 2012; 118(17): 4139–4147.
29. Kilari D., Pandya C., Fung C., Sahasrabudhe D., Brasacchio R., Messing E. Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). ASCO Meeting Abstracts 2013, 31(Suppl 6); 226.
30. Berthold D., Pond G., Soban F., de Wit R., Eisenberger M., Tannock I. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242–245.
31. Italiano A., Ortholan C., Oudard S., Pouessel D., Gravis G., Beuzeboc P., Bompas E., Fléchon A., Joly F., Ferrero J.M., Fizazi K. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368–1375.
32. de Bono J., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., Bodrogi I., Mackenzie M.J., Shen L., Roessner M., Gupta S., Sartor A.O.; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154.
33. Bahl A., Oudard S., Tombal B., Ozgüroglu M., Hansen S., Kocak I., Gravis G., Devin J., Shen L., de Bono J.S., Sartor A.O.; TROPIC Investigators. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013; 24: 2402–2408.
34. Hurria A., Togawa K., Mohile S., Owusu C., Klepin H.D., Gross C.P., Lichtman S.M., Gajra A., Bhatia S., Katheria V., Klapper S., Hansen K., Ramani R., Lachs M., Wong F.L., Tew W.P. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457–3465.
35. Extermann M., Boler I., Reich R., Lyman G.H., Brown R.H., DeFelice J., Levine R.M., Lubiner E.T., Reyes P., Schreiber F.J. 3rd, Balducci L. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118: 3377–3386.
36. Parker C., Nilsson S., Heinrich D. Helle S.I., O'Sullivan J.M., Fosså S.D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., Hoskin P., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall'Oglio M., Franzén L., Coleman R., Vogelzang N.J., O'Bryan-Tear C.G., Staudacher K., Garcia-Vargas J., Shan M., Bruland Ø.S., Sartor O.; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]